Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Celyad 2024

699 Posts
Pagina: «« 1 ... 18 19 20 21 22 ... 35 »» | Laatste | Omlaag ↓
  1. Garre 9 augustus 2024 10:18

    • Garre

      Lid sinds: 13 jun 2019

      Laatste bezoek: 12 mrt 2025

    • Aanbevelingen

      Ontvangen: 157

      Gegeven: 2

    •    Aantal posts: 2.212

    Diegy, waar is die persoon gebleven. Denk dat ie alles opkoopt.
    Het is al augustus... wat hebben we gehoord en gezien vanuit celyad? Ze zijn nu vast op vakantie na al dat harde werken ook wel verdiend toch.
    Zal er ooit nog iets gecommuniceerd worden.
  2. Buskie 16 augustus 2024 12:56

    • Buskie

      Lid sinds: 25 sep 2018

      Laatste bezoek: 11 mrt 2025

    • Aanbevelingen

      Ontvangen: 71

      Gegeven: 11

    •    Aantal posts: 319

    Ik kijk teveel. Vanmorgen hold op 0.22
    Staan er 32000 in de bied op bestens.
    Krijgt ze bij herstart allemaal voor 0.248... vreemd
  5. Garre 17 augustus 2024 22:04

    • Garre

      Lid sinds: 13 jun 2019

      Laatste bezoek: 12 mrt 2025

    • Aanbevelingen

      Ontvangen: 157

      Gegeven: 2

    •    Aantal posts: 2.212

    Ja man, iedereen is eruit denk... en niks geen nieuws... ben zo benieuwd wat ze nou elke dag nog doen bij celyad.
  10. Garre 20 augustus 2024 16:57

    • Garre

      Lid sinds: 13 jun 2019

      Laatste bezoek: 12 mrt 2025

    • Aanbevelingen

      Ontvangen: 157

      Gegeven: 2

    •    Aantal posts: 2.212

    Joh dannyb44... als het even stokt de handel zakt dit aandeel procentueel soms hard .... maar joh het is een paar centen kwestie geworden. En celyad interesseert dat geen reet. Als ze maar loon hebben...
  11. Garre 20 augustus 2024 17:05

    • Garre

      Lid sinds: 13 jun 2019

      Laatste bezoek: 12 mrt 2025

    • Aanbevelingen

      Ontvangen: 157

      Gegeven: 2

    •    Aantal posts: 2.212

    En er zitten ook wat grappenmakers bij, die soms met 1 stukje alles willen laten zakken.... het is niet serieus meer te nemen helaas.
  16. Garre 3 september 2024 09:17

    • Garre

      Lid sinds: 13 jun 2019

      Laatste bezoek: 12 mrt 2025

    • Aanbevelingen

      Ontvangen: 157

      Gegeven: 2

    •    Aantal posts: 2.212

    Niks geen nieuws meer gezien of gehoord laatste 4 maanden.
    Wat mogen we nog wel verwachten? Iemand nog contact gehad met celyad?
  17. Lament 4 september 2024 09:04

    • Lament

      Lid sinds: 12 dec 2023

      Laatste bezoek: 11 mrt 2025

    • Aanbevelingen

      Ontvangen: 13

      Gegeven: 27

    •    Aantal posts: 41

    quote:

    Garre schreef op 3 september 2024 09:17:

    Niks geen nieuws meer gezien of gehoord laatste 4 maanden.
    Wat mogen we nog wel verwachten? Iemand nog contact gehad met celyad?
    Ik kom hier ook haast dagelijks piepen maar niks.... :/
  18. forum rang 6 Voorheen_bekend_als_Test 13 september 2024 07:08

    • Voorheen_bekend_als_Test

      Lid sinds: 26 okt 2023

      Laatste bezoek: 12 mrt 2025

    • Aanbevelingen

      Ontvangen: 1013

      Gegeven: 832

    •    Aantal posts: 1.738

    Celyad Oncology reports first half year 2024 financial results and recent business highlights
    September 13, 2024

    - The Company continues to bolster its intellectual property estate and to pursue options to monetize it
    - The Company’s two main research and development platforms have delivered proof-of-concept and are ready to be incorporated into clinical candidates and/or to be further explored and exploited via potential partnerships

    - The Company actively participated at several key international scientific conferences and published in well-renowned peer-reviewed journals which have raised the interest for the Company’s technologies and developments

    - Operational expenses according to Budget allowing cash runway until third quarter 2025

    Michel Lussier, interim Chief Executive Officer of Celyad Oncology, commented: “Celyad Oncology continues to make remarkable progress in developing cutting-edge technologies for chimeric antigen receptor (CAR) T-cell therapy. Our groundbreaking multiplex platform is revolutionizing the potential of CAR T-cells, while our pioneering NKG2D-based multispecific CAR T-cell platform is further paving the way to conquer current limitations of this transformative class of immunotherapy”

    H1-2024 Business highlights
    - The Company is pursuing a strategy of continued research and development, with a particular focus on intellectual property (IP). Monetization of its innovative approaches and technologies is a key objective. Celyad Oncology is progressing in this regard and is currently in discussion with potential partners for out-licensing deals;
    - With its research focus, the Company has made concrete progress by providing proof-of-concept of the multiplex short hairpin RNAs (shRNAs) non-gene edited technology platform and the multispecific NKG2D-based CAR T-cell platform, which provide unique options to tackle the major current limitations of CAR T-cell therapies. Options to further explore or validate these data through strategic partnerships, and/or to incorporate these technologies into clinical CAR-T candidates are actively pursued by the Company;
    - The Company continues to share and discuss its latest advances at international scientific conferences throughout the first half of 2024 with updated results provided at the 27th ASGCT [1] Annual Meeting and the Recent insights into Immuno-Oncology VIB conference [2].
    The Company is also focusing on sharing data and views with the scientific community and has published a review highlighting the interest of non-gene editing technologies for allogeneic CAR T-cell therapies in Cells [3] and another review providing an overview of all engineering strategies to safely drive CAR T-cells into the future in Frontiers in Immunology [4], two well-renowned peer-reviewed scientific journals;
    - In response to the request expressed by several companies and academic institutions engaged in gene and cell therapies for cardiac applications, the Company has re-initiated the manufacturing and commercialization of C-Cath®, an intra-myocardial injection catheter developed and owned by the Company.

    H1-2024 operational highlights
    - Multiplex shRNA non-gene edited technology – The Company developed a chimeric micro-RNA (miRNA) cluster to enable multiplexing of shRNAs, designed for easy, efficient, and tunable downregulation of up to four target genes simultaneously in CAR T-cells.
    -- Data successfully demonstrated the feasibility and effectiveness of the multiplex approach to improve allogeneic CAR T-cell viability by avoiding graft-versus-host disease (GvHD) via knocking down of CD3?, avoiding host-versus-graft (HvG) reaction and promoting cell persistence via knocking-down of ß2M and CIITA, and avoiding CD95L-induced autophagy via knocking-down of CD95;
    -- Another multiplex cassette focusing on the knock-down of co-inhibitory receptors (PD-1, LAG-3, TIM-3 and CD95) was also developed to decrease the expression of exhaustion markers at the surface of CAR T-cells.

    - Multispecific NKG2D-based CAR T-cell platform – Different NKG2D-based multispecific CAR T-cells were developed to provide the proof-of-concept that NKG2D ligands (NKG2DL) are valuable targets in a multispecific CAR approach to counteract relapses due to antigen loss or antigen heterogeneity.
    -- PSMA/NKG2DL tandem CAR T-cells, that encompass the extracellular domain of the natural NKG2D receptor fused to an anti-PSMA CAR to overcome antigen heterogeneity and improve anti-tumor efficacy against prostate cancer were developed and demonstrated functionality in vitro against prostate cancer cell lines expressing or not the tumor-associated antigen PSMA;
    -- In vivo proof-of-concept of the company’s CD19/NKG2DL tandem CAR T-cell candidate was also provided in a B-ALL relapse model, showing that this multi-specific CAR T-cell candidate has an enhanced anti-tumor efficacy against heterogeneous lymphoma tumors, or to counteract antigen loss, as compared to currently existing treatment options.
  19. forum rang 6 Voorheen_bekend_als_Test 13 september 2024 07:08

    • Voorheen_bekend_als_Test

      Lid sinds: 26 okt 2023

      Laatste bezoek: 12 mrt 2025

    • Aanbevelingen

      Ontvangen: 1013

      Gegeven: 832

    •    Aantal posts: 1.738

    First Half 2024 financial review
    As of June 30, 2024, the Company’s Treasury position amounts to €6.2 million.

    After due consideration of detailed budgets and estimated cash flow forecasts for the years 2024 and 2025, the Company projects that its existing cash and cash equivalents will be sufficient to fund its estimated operating and capital expenditures into the third quarter of 2025.

    Research and Development (R&D) expenses were €1.5 million in June 2024 as compared to €2.1 million during the same period in 2023, a decrease of €0.6 million. The decrease in the Company’s R&D expenses is primarily driven by the Company’s strategic decision in 2022 and beginning of 2023 to discontinue clinical development and prioritization of most promising research programs.

    General and Administrative (G&A) expenses were €1.7 million in June 2024 as compared to €3.7 million during the same period in 2023, a decrease of €2.0 million. This decrease is mainly related to the decrease in employee expenses related to headcount reduction and management changes to support the Company’s reorganization (notably resulting from Nasdaq delisting and SEC deregistration of the Company) and to a decrease in insurance costs and consulting fees.

    As of June 30, 2024, Management has determined that there has been no event (such as a firm sublicense or collaboration contract) that led to a change in fair value of the contingent consideration and other financial liabilities. The Company’s other income is mainly associated with grants received and some insurance compensations.

    Net loss for the first half of 2024, was €3.0 million, or € (0.07) per share, compared to a net loss of €3.7 million, or € (0.17) per share, for the same period in 2023. As noted above, the decrease in net loss between periods was primarily due to the decrease of R&D and General and administrative expenses in 2024 partly compensated by lower amounts of grants revenues from public institutions.

    Net cash used in operations was €2.8 million for the first half of 2024 compared to €8.3 million for the first half of 2023. The decrease of €5.5 million is primarily driven by the global decrease in preclinical and clinical activities, insurance costs and headcount. In 2023 the deviation between Net cash used in operations and Loss of the period was mainly explained by the change in the working capital (Trade payables and other liabilities decrease). The decrease of these costs is in line with the Company’s decision to adopt and implement over the last few months of the year 2022 the new business strategy to focus on early-stage discovery research in areas of expertise where it can leverage the differentiated nature of its platforms.

    Upcoming anticipated milestones
    - More data and evidence in the context of the multispecific CAR and shRNA multiplex platforms, with the possibility of a clinical evaluation of assets and initiation of clinical trials either by the Company and/or through strategic partnerships afterwards;
    - Celyad Oncology will attend and present updated data on its programs at the 9th CAR-TCR Summit in Boston, US (Sep. 17-20), the Advanced Therapies Europe in Estoril (Sep. 10-12) and present two posters at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston (Nov. 6-10);
    - The Company anticipates the appointment of a new CEO in the second half of 2024.
699 Posts
Pagina: «« 1 ... 18 19 20 21 22 ... 35 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.101
AB InBev 2 5.529
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.890
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.794
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.772
Aedifica 3 925
Aegon 3.258 322.987
AFC Ajax 538 7.088
Affimed NV 2 6.299
ageas 5.844 109.897
Agfa-Gevaert 14 2.060
Ahold 3.538 74.343
Air France - KLM 1.025 35.239
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.046
Alfen 16 25.070
Allfunds Group 4 1.511
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 408
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.578
AMG 971 134.068
AMS 3 73
Amsterdam Commodities 305 6.740
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.029
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.789
Arcelor Mittal 2.034 320.873
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.341
Aroundtown SA 1 221
Arrowhead Research 5 9.749
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.559
ASML 1.766 109.389
ASR Nederland 21 4.505
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.728
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.412

Macro & Bedrijfsagenda

  1. 12 maart

    1. Faillissementen februari (NL)
    2. Basic-Fit Q4-cijfers
    3. Rheinmetall Q4-cijfers
    4. Hypotheekaanvragen - wekelijks (VS)
    5. Inflatie februari (VS) +2,9% YoY (versus 3% in januari). Kerninflatie: +3,2% YoY (versus 3,3%) volitaliteit verwacht
    6. Olievoorraden - wekelijks (VS)
    7. Adobe Q1-cijfers

  2. 13 maart

    1. Pharming Q4-cijfers
    2. HelloFresh Q4-cijfers
    3. Deliveroo Q4-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda